Biomarkers of pathophysiology in hypertrophic cardiomyopathy: Implications for clinical management and prognosis

European Heart Journal

Volumn 30, Issue 2, 2009, Pages 139-151

  Cambronero, Francisco ^a   Marín, Francisco ^a   Roldán, Vanessa ^b   Hernández Romero, Diana ^a   Valdés, Mariano ^a   Lip, Gregory Y H ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Biomarkers; Hypertrophic cardiomyopathy; Pathophysiology

Indexed keywords

BIOLOGICAL MARKER; GROWTH FACTOR; HORMONE; MATRIX METALLOPROTEINASE; NATRIURETIC FACTOR;

APOPTOSIS; DISEASE COURSE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW;

BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; ENDOTHELIUM, VASCULAR; HUMANS; MODELS, BIOLOGICAL; PROGNOSIS;

EID: 58449108642     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn538     Document Type: Review

References (135)

1. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84:476-482.
2. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-789.
3. Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation 2006;113:e858-e862.
4. Hardarson T, De la Calzada CS, Curiel R, Goodwin JF. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet 1973;2:1462-1467.
5. Furlan AJ, Craciun AR, Raju NR, Hart N. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. Stroke 1984;15:282-284.
6. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064-1075.
7. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-1320.
8. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 2006;113:e72-e75.
9. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation 2006;113:e152-e155.
10. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part III: biomarkers of oxidative stress and angiogenic growth factors. Circulation 2006;113:e289-e292.
11. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part IV: matrix metalloproteinases and biomarkers of platelet activation. Circulation 2006;113:e382-e385.
12. Moe GW. B-type natriuretic peptide in heart failure. Curr Opin Cardiol 2006;21:208-214.
13. Ferrans VJ, Morrow AG, Roberts WC. Myocardial ultrastructure in idiopathic hypertrophic subaortic stenosis. A study of operatively excised left ventricular outflow tract muscle in 14 patients. Circulation 1972;45:769-792.
14. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127- 133.
15. Factor SM, Butany J, Sole MJ, Wigle ED, Williams WC, Rojkind M. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1991;17:1343-1351.
16. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ('small vessel') coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545-557.
17. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986;55:575-581.
18. Schwartzkopff B, Mundhenke M, Strauer BE. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J Am Coll Cardiol 1998;31:1089-1096.
19. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Matsuda M, Hamashima Y, Kawai C. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987;75:1130-1139.
20. Takemura G, Takatsu Y, Fujiwara H. Luminal narrowing of coronary capillaries in human hypertrophic hearts: an ultrastructural morphometrical study using endomyocardial biopsy specimens. Heart 1998;79:78-85.
21. Suzuki H, Koba S, Katagiri T, Takeyama Y, Suwa Y. Ultrastructural changes of blood capillaries in patients with microvascular angina, hypertrophic cardiomyopathy, and dilated cardiomyopathy. Am J Cardiovasc Pathol 1995;5:19-26.
22. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 1998;83:580-593.
23. Blanchard E, Seidman C, Seidman JG, LeWinter M, Maughan D. Altered cross-bridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circ Res 1999;84:475-483.
24. Lin D, Bobkova A, Homsher E, Tobacman LS. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J Clin Invest 1996;97:2842-2848.
25. Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest 1998;102:1292-1300.
26. Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL, Schwartz S, Robbins J, Leinwand LA. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 1998;101:2800-2811.
27. Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ Res 1999;85:841-847.
28. Kim SJ, Iizuka K, Kelly RA, Geng YJ, Bishop SP, Yang G, Kudej A, McConnell BK, Seidman CE, Seidman JG, Vatner SF. An alpha-cardiac myosin heavy chain gene mutation impairs contraction and relaxation function of cardiac myocytes. Am J Physiol 1999;276:H1780-H1787.
29. Spindler M, Saupe KW, Christe ME, Sweeney HL, Seidman CE, Seidman JG, Ingwall JS. Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest 1998;101:1775-1783.
30. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000;355:58-60.
31. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41:1776-1782.
32. Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem 2000;275:22069-22074.
33. Michele DE, Albayya FP, Metzger JM. Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes. Nat Med 1999;5:1413-1417.
34. Muthuchamy M, Pieples K, Rethinasamy P, Hoit B, Grupp IL, Boivin GP, Wolska B, Evans C, Solaro RJ, Wieczorek DF. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Circ Res 1999;85:47-56.
35. Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 2003;19:263-268.
36. Merante F, Tein I, Benson L, Robinson BH. Maternally inherited hypertrophic cardiomyopathy due to a novel T-to-C transition at nucleotide 9997 in the mitochondrial tRNA(glycine) gene. Am J Hum Genet 1994;55:437-446.
37. Lodi R, Cooper JM, Bradley JL, Manners D, Styles P, Taylor DJ, Schapira AH. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA 1999;96:11492-11495.
38. Tanaka T, Sohmiya K, Kawamura K. Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy? J Mol Cell Cardiol 1997;29:121-127.
39. Aoyama T, Souri M, Ushikubo S, Kamijo T, Yamaguchi S, Kelley RI, Rhead WJ, Uetake K, Tanaka K, Hashimoto T. Purification of human very-long-chain acylcoenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest 1995;95:2465-2473.
40. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001;10:1215-1220.
41. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-1831.
42. Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nat Med 2000;6:1221-1227.
43. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
44. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004;109:1580-1589.
45. Chiu C et al. Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2007;43:337-343.
46. Tsoutsman T, Lam L, Semsarian C. Genes, calcium and modifying factors in hypertrophic cardiomyopathy. Clin Exp Pharmacol Physiol 2006;33:139-145.
47. Zen K, Irie H, Doue T, Takamiya M, Yamano T, Sawada T, Azuma A, Matsubara H. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy. Int Heart J 2005;46:231-244.
48. Hogye M, Mandi Y, Csanady M, Sepp R, Buzas K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol 2004;94:249-251.
49. Nagueh SF, Stetson SJ, Lakkis NM, Killip D, Perez-Verdia A, Entman ML, Spencer WH 3rd, Torre-Amione G. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1844-1850.
50. Buzas K, Megyeri K, Hogye M, Csanady M, Bogats G, Mandi Y. Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies. Eur Cytokine Netw 2004;15:53-59.
51. Mandi Y, Hogye M, Talha EM, Skolak E, Csanady M. Cytokine production and antibodies against heat shock protein 60 in cardiomyopathies of different origins. Pathobiology 2000;68:150-158.
52. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998;97:1375-1381.
53. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995;92:4862-4866.
54. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJ, Sabbadini RA. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854-2865.
55. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 1994;105:897-904.
56. Narula J, Haider N, Arbustini E, Chandrashekhar Y. Mechanisms of disease: apoptosis in heart failure-seeing hope in death. Nat Clin Pract Cardiovasc Med 2006;3:681-688.
57. Febbraio MA, Pedersen BK. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev 2005;33:114-119.
58. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-1378.
59. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-a provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997;95:1247-1252.
60. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993;74:845-853.
61. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, Feldman AM. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 2000;97:12746-12751.
62. Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997;81:187-195.
63. Patel R, Lim DS, Reddy D, Nagueh SF, Lutucuta S, Sole MJ, Zoghbi WA, Quiñones MA, Roberts R, Marian AJ. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000;32:2369-2377.
64. Penicka M, Gregor P, Krupicka J, Jira M. Tumour necrosis factor-alpha soluble receptors type I are related to symptoms and left ventricular function in hypertrophic cardiomyopathy. Can J Cardiol 2001;17:777-784.
65. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation 1995;92:1379-1382.
66. Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation. Heart 2008;94:e21.
67. Payá E, Marín F, González J, Gimeno J, Feliu E, Romero A, Ruiz-Espejo F, Roldán V, Climent V, de la Morena G, Valdés M. Variables associated with contrast enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. J Card Fail 2008;14:414-419.
68. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007;115:1398-1407.
69. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992;148:1274-1279.
70. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-1762.
71. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. Fas ligand in human serum. Nat Med 1996;2:317-322.
72. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
73. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-840.
74. Kodama K, Shigematsu Y, Hamada M, Hiwada K, Kazatani Y, Matsuzaki K, Murakami E. The effect of coronary vasospasm on the direction of ST-segment deviation in patients with both hypertrophic cardiomyopathy and vasospastic angina. Chest 2000;117:1300-1308.
75. Misawa K, Nitta Y, Matsubara T, Oe K, Kiyama M, Shimizu M, Mabuchi H. Difference in coronary blood flow dynamics between patients with hypertension and those with hypertrophic cardiomyopathy. Hypertens Res 2002;25:711-716.
76. Dimitrow PP, Krzanowski M, Grodecki J, Malecka B, Lelakowski J, Kawecka-Jaszcz K, Szczeklik A, Dubiel JS. Verapamil improves the pacing-induced vasodilatation in symptomatic patients with hypertrophic cardiomyopathy. Int J Cardiol 2002;83:239-247.
77. Dimitrow PP, Krzanowski M, Nizankowski R, Szczeklik A, Dubiel JS. Verapamil improves the response of coronary vasomotion to cold pressor test in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy. Cardiovasc Drugs Ther 1999;13:259-264.
78. Knaapen P, Germans T, Camici PG, Rimoldi OE, ten Cate FJ, ten Berg JM, Dijkmans PA, Boellaard R, van Dockum WG, Gotte MJ, Twisk JW, van Rossum AC, Lammertsma AA, Visser FC. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2008;294:H986-H993.
79. Lip GY, Foster W, Blann AD. Plasma von Willebrand factor levels and surrogates of atherosclerosis. J Thromb Haemost 2005;3:659-661.
80. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-265.
81. Varol E, Ozaydin M, Sahin M, Altinbas A, Kosar F. vWf levels as a circulating marker of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Indian Heart J 2005;57:655-657.
82. Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep 2007;59:715-720.
83. Stroud RE, Deschamps AM, Lowry AS, Hardin AE, Mukherjee R, Lindsey ML, Ramamoorthy S, Zile MR, Spencer WH, Spinale FG. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail 2005;11:124-130.
84. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi K, Marumo F. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209-215.
85. Hasegawa K, Fujiwara H, Koshiji M, Inada T, Ohtani S, Doyama K, Tanaka M, Matsumori A, Fujiwara T, Shirakami G, Hosoda K, Nakao K, Sasayama S. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 1996;27:259-264.
86. Ogino K, Ogura K, Kinugawa T, Osaki S, Kato M, Furuse Y, Kinugasa Y, Tomikura Y, Igawa O, Hisatome I, Shigemasa C. Neurohumoral profiles in patients with hypertrophic cardiomyopathy: differences to hypertensive left ventricular hypertrophy. Circ J 2004;68:444-450.
87. Ito H, Hiroe M, Hirata Y, Fujisaki H, Adachi S, Akimoto H, Ohta Y, Marumo F. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994;89:2198-2203.
88. Yorikane R, Sakai S, Miyauchi T, Sakurai T, Sugishita Y, Goto K. Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett 1993;332:31-34.
89. Yarom R, Lewis BS, Lijovetzky G, Havivi Y, Chandler JA. Platelet studies in patients with hypertrophic cardiomyopathy. Cardiovasc Res 1982;16:324-330.
90. Riazanov AS, Gabbasov ZA, Iurenev AP. Platelet aggregation in patients with hypertrophic cardiomyopathy. Ter Arkh 2000;72:36-38.
91. Heldin CH, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1990;1:555-566.
92. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986;46:155-169.
93. Suzuki J, Baba S, Ohno I, Endoh M, Nawata J, Miura S, Yamamoto Y, Sekiguchi Y, Takita T, Ogata M, Tamaki K, Ikeda J, Shirato K. Immunohistochemical analysis of platelet-derived growth factor-B expression in myocardial tissues in hypertrophic cardiomyopathy. Cardiovasc Pathol 1999;8:223-231.
94. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995;25:1634-1640.
95. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868.
96. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
97. Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 2006;69:666-676.
98. Fassbach M, Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 2005;94:328-335.
99. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M, D'Alessandro G, Cacace A, Ciampi Q, Chiariello M. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003;108:1455-1460.
100. Noji Y, Shimizu M, Ino H, Higashikata T, Yamaguchi M, Nohara A, Horita T, Shimizu K, Ito Y, Matsuda T, Namura M, Mabuchi H. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 2004;68:355-360.
101. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002;27:92-98.
102. Roldán V, Marín F, Gimeno J, Ruíz-Espejo F, Gonzalez J, Feliu J, García-Honrubia A, Saura D, de la Morena G, Valdés M, Vicente V. Matrix metalloproteinases and tissue remodelling in hypertrophic myocardiopathy. Am Heart J 2008;156:85-91.
103. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000;35:36-44.
104. Bauersachs J, Stork S, Kung M, Waller C, Fidler F, Hoyer C, Frantz S, Weidemann F, Ertl G, Angermann CE. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur J Clin Invest 2007;37:852-859.
105. Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 2006;47:827-834.
106. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001;103:789-791.
107. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, DeFreitas G, Entman M, Carabello BA, Roberts R, Marian AJ. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004;109:1284-1291.
108. Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 2005;96:1563-1567.
109. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, Zennaro MC, Lombes M. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 2001;276:38911-38920.
110. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003;93:69-76.
111. Le Roith D. Insulin-like growth factors. N Engl J Med 1997;336:633-640.
112. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999;31:2049-2061.
113. Li G, Li RK, Mickle DA, Weisel RD, Merante F, Ball WT, Christakis GT, Cusimano RJ, Williams WG. Elevated insulin-like growth factor-I and transforming growth factor-beta 1 and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy. A possible mechanism. Circulation 1998;98:II144-II149. discussion II149-II150.
114. Saeki H, Hamada M, Hiwada K. Circulating levels of insulin-like growth factor-1 and its binding proteins in patients with hypertrophic cardiomyopathy. Circ J 2002;66:639-644.
115. Sato Y, Taniguchi R, Nagai K, Makiyama T, Okada H, Yamada T, Matsumori A, Takatsu Y. Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy. Heart 2003;89:659-660.
116. Pop GA, Cramer E, Timmermans J, Bos H, Verheugt FW. Troponin I release at rest and after exercise in patients with hypertrophic cardiomyopathy and the effect of betablockade. Arch Cardiol Mex 2006;76:415-418.
117. Brito D, Matias JS, Sargento L, Cabral MJ, Madeira HC. Plasma N-terminal probrain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy. Rev Port Cardiol 2004;23:1557-1582.
118. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993;341:1109-1113.
119. Derchi G, Bellone P, Chiarella F, Randazzo M, Zino V, Vecchio C. Plasma levels of atrial natriuretic peptide in hypertrophic cardiomyopathy. Am J Cardiol 1992;70:1502-1504.
120. Fahy GJ, McCreery CJ, O'sullivan F, Keenan AK, Quigley PJ, Maurer BJ. Plasma atrial natriuretic peptide is elevated in patients with hypertrophic cardiomyopathy. Int J Cardiol 1996;55:149-155.
121. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, Mukoyama M, Nakao K, Imura H, Sasayama S. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372- 380.
122. Yoshibayashi M, Kamiya T, Saito Y, Matsuo H. Increased plasma levels of brain natriuretic peptide in hypertrophic cardiomyopathy. N Engl J Med 1993;329:433-434.
123. Magga J, Sipola P, Vuolteenaho O, Risteli J, Jääskeläinen P, Peuhkurinen K, Kuusisto J. Significance of plasma levels of N-Terminal pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the tropomyosin gene. Am J Cardiol 2008;101:1185-1190.
124. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, Cohn JN. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 2004;109:984-989.
125. Okawa M, Kitaoka H, Matsumura Y, Kubo T, Yamasaki N, Furuno T, Doi Y. Functional assessment by myocardial performance index (Tei index) correlates with plasma brain natriuretic peptide concentration in patients with hypertrophic cardiomyopathy. Circ J 2005;69:951-957.
126. Arteaga E, Araujo AQ, Buck P, Ianni BM, Rabello R, Mady C. Plasma aminoterminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J 2005;150:1228-1232.
127. Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, Basaran Y. Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 2006;98:1504-1506.
128. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, Collinson PO, McKenna WJ, Elliott PM. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 2006;98:515-519.
129. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, Oda H, Watanabe S, Morita N, Nakao K, Fujiwara H. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996;28:1234-1242.
130. Khan K, Talwar S. Screening for familial hypertrophic cardiomyopathy using brain natriuretic peptide. Eur Heart J 1999;20:550.
131. Kitaoka H, Hitomi N, Yabe T, Furuno T, Doi YL. Cardiovascular events and plasma atrial natriuretic peptide level in patients with hypertrophic cardiomyopathy. Am J Cardiol 2001;87:1318-1320.
132. Matsuura H, Murakami T, Hina K, Yamamoto K, Kawamura H, Sogo T, Shinohata R, Usui S, Ninomiya Y, Kusachi S. Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy. Clin Biochem 2008;41:134-139.
133. Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, Kimura A, Kato H, Imaizumi T. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 1998;83:594-601.
134. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-324.
135. Pieroni M, Bellocci F, Sanna T, Verardo R, Ierardi C, Maseri A, Frustaci A, Crea F. Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Card Fail 2007;13:380-388.